About this trial
Congestive heart failure (CHF) remains a major cause of morbidity, rehospitalization, and mortality worldwide, particularly among elderly and polymorbid patients. Systemic congestion is its most characteristic clinical manifestation and the leading cause of hospitalization for acute heart failure. Standard treatment relies on loop diuretics, primarily furosemide, to reduce fluid overload and alleviate congestive symptoms. However, in clinical practice, many patients exhibit an inadequate diuretic response or resistance to furosemide, particularly in the context of cardiorenal syndrome (CRS), where cardiac and renal dysfunction mutually exacerbate each other. This profile, frequently observed in advanced stages of heart failure, significantly limits the effectiveness of guideline-directed medical therapies (GDMTs), particularly SGLT2 inhibitors, mineralocorticoid receptor antagonists, and angiotensin-converting enzyme (ACE) inhibitors, whose use is often restricted by hypotension, hyperkalemia, or impaired renal function.
Thus, in this subgroup of patients, conventional pharmacological approaches encounter a therapeutic barrier, necessitating the search for alternative or complementary strategies targeting sodium and water depletion without compromising renal perfusion. In this context, the combined administration of hypertonic saline (HS) and furosemide has been proposed as a pathophysiologically sound approach to break the vicious cycle of cardiorenal syndrome. Hypertonic saline solution (HSS) acts by restoring effective intravascular volume, improving renal perfusion, and promoting more efficient natriuresis through better furosemide delivery to the distal nephron. Pioneering studies by Paterna et al. showed that the concomitant administration of HSS (1.4-3% NaCl, 150-250 mL) and intravenous furosemide increased diuresis, improved the hemodynamic profile, and reduced the length of hospital stay and readmission rates without deterioration of renal function.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Chronic renal insufficiency (serum creatinine > 150 µg/ml)
Diagnosis of heart failure (preserved or reduced LVEF)
Signed informed consent
Disqualifiers
Severe hyponatremia (<130 mmol/L) or hypernatremia (>150 mmol/L),
History of allergic reaction to HSS or furosemide
Shock or hemodynamic instability
Pregnancy or breastfeeding
Trial design
Parallel
Treatments tested in this trial
Hypertonic sodium chloride 10%
Drug50 mL of 10% hypertonic sodium chloride (NaCl)
Sodium Chloride 0.9%
Drug50 mL of 0.9% sodium chloride (NaCl)
Furosemide intravenous solution
DrugFurosemide 250 mg administered intravenously over 60 minutes once weekly for 2 months.
Treatment groups
Trial outcomes
Primary outcomes
Number of participants rehospitalized for heart failure
Description: Number of participants requiring rehospitalization for heart failure during follow-up.
All-cause mortality
Description: Number of deaths from any cause during follow-up.
Secondary outcomes
Serum creatinine level
Evaluation of serum creatinine levels.
Blood urea level
Evaluation of blood urea levels.
BNP or NT-proBNP concentration
Evaluation of BNP or NT-proBNP levels.
Quality of life and patient satisfaction score assessed using a Likert scale
Description: Assessment of quality of life and patient satisfaction using a 5-point Likert scale ranging from 1 to 5, where: 1 = very dissatisfied/very poor quality of life 5 = very satisfied/excellent quality of life Higher scores indicate better patient satisfaction and quality of life.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: